Latest News and Press Releases

INDIANAPOLIS, March 22, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...

Learn what “PNT2002 has a favorable and safe dosimetry profile in the patient population and dose regimen being studied” means in the context of radiopharmaceuticals Register online at...

Dosimetry data demonstrated PNT2002 has a​ favorable and safe dosimetry profile in the patient population and dose regimen being studied Red marrow dosimetry was well below critical thresholds,...

INDIANAPOLIS, Feb. 17, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...

Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) inhibitor program, planned for summer 2022 Initiated IND-enabling studies for...

Company’s radiopharmaceutical manufacturing facility now operational, supplying doses for the Phase 3 SPLASH trial – view the facility at manufacturing.pointbiopharma.com Will receive actinium-225 in...

INDIANAPOLIS, Jan. 04, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life...

Justyna Kelly promoted to COO, Dr. Robin Hallett promoted to VP, Discovery and Translational Sciences, Dr. Sherin Al-Safadi to join as VP Medical Affairs, and Michael Gottlieb (CCO) to depart the...

INDIANAPOLIS and MOL, Belgium , Nov. 24, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing...

POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations Register online at https://hub.pointbiopharma.com/dec2021 ...